Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches

Chronic myeloid leukemia (CML) is a stem cell disease, in which the BCR/ABL oncoprotein is considered essential for abnormal growth and accumulation of neoplastic cells. During the past 10 years, the BCR/ABL tyrosine kinase inhibitor imatinib (STI571) has successfully been introduced in the treatmen...

Descripción completa

Detalles Bibliográficos
Autor principal: Valent, Peter
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721289/
https://www.ncbi.nlm.nih.gov/pubmed/19707313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721289/
https://www.ncbi.nlm.nih.gov/pubmed/19707313

Ejemplares similares